Kiniksa Pharmaceuticals International (KNSA) Financials

$58.60 +1.67 (+2.93%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$58.60 -0.01 (-0.01%)

As of 05/8/2026 05:40 PM Eastern

Annual Income Statements for Kiniksa Pharmaceuticals International

This table shows Kiniksa Pharmaceuticals International's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-65	-103	-162	-161	-158	183	14	-43	59
Consolidated Net Income / (Loss)	-65	-103	-162	-161	-158	183	14	-43	59
Net Income / (Loss) Continuing Operations	-65	-103	-162	-161	-158	183	14	-43	59
Total Pre-Tax Income	-65	-103	-164	-156	-157	11	-17	-36	89
Total Operating Income	-65	-108	-170	-157	-157	9.77	-25	-46	77
Total Gross Profit	0.00	0.00	0.00	0.00	29	173	180	234	370
Total Revenue	0.00	0.00	0.00	0.00	39	220	270	423	678
Operating Revenue	-	-	0.00	0.00	39	220	270	423	678
Total Cost of Revenue	0.00	0.00	0.00	0.00	9.94	47	90	189	307
Operating Cost of Revenue	-	-	0.00	0.00	9.94	47	90	189	307
Total Operating Expenses	65	108	170	157	185	163	206	280	293
Selling, General & Admin Expense	9.04	22	35	45	86	98	129	168	196
Research & Development Expense	56	87	135	112	99	65	76	112	97
Total Other Income / (Expense), net	0.53	4.72	6.05	1.13	0.10	1.25	8.54	9.46	12
Other Income / (Expense), net	-	-	-	1.13	0.10	1.25	8.54	9.46	12
Income Tax Expense	0.00	-0.21	-2.05	5.15	1.39	-172	-31	7.04	30
Basic Earnings per Share	($35.85)	($3.49)	($2.99)	($2.61)	($2.30)	$2.64	$0.20	($0.60)	$0.80
Weighted Average Basic Shares Outstanding	1.81M	29.55M	54.05M	61.84M	68.58M	69.38M	70.06M	71.42M	74.20M
Diluted Earnings per Share	($35.85)	($3.49)	($2.99)	($2.61)	($2.30)	$2.60	$0.20	($0.60)	$0.75
Weighted Average Diluted Shares Outstanding	1.81M	29.55M	54.05M	61.84M	68.58M	70.42M	71.92M	71.42M	78.98M
Weighted Average Basic & Diluted Shares Outstanding	1.81M	29.55M	54.05M	61.84M	138.21M	139.51M	141.23M	145.29M	153.07M

This table shows Kiniksa Pharmaceuticals International's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-14	25	-18	-3.99	-13	-8.90	8.54	18	18	14	23
Consolidated Net Income / (Loss)	-14	25	-18	-3.91	-13	-8.89	8.54	18	18	14	23
Net Income / (Loss) Continuing Operations	-14	25	-18	-3.91	-13	-8.89	8.54	18	18	14	23
Total Pre-Tax Income	-8.50	2.45	-14	2.30	-7.20	-17	16	23	27	23	33
Total Operating Income	-11	0.08	-17	-0.12	-9.66	-19	13	20	24	20	29
Total Gross Profit	41	57	48	66	63	56	76	86	97	111	118
Total Revenue	67	83	80	109	112	123	138	157	181	202	214
Operating Revenue	67	83	80	109	112	123	138	157	181	202	214
Total Cost of Revenue	26	27	31	42	49	66	62	71	84	91	96
Operating Cost of Revenue	26	27	31	42	49	66	62	71	84	91	96
Total Operating Expenses	52	57	65	66	72	76	63	66	73	91	89
Selling, General & Admin Expense	34	37	39	42	46	41	44	47	49	57	61
Research & Development Expense	17	20	26	24	26	35	19	19	24	35	27
Total Other Income / (Expense), net	2.43	2.37	2.27	2.42	2.46	2.32	2.29	2.72	3.14	3.50	3.41
Other Income / (Expense), net	2.43	2.37	2.27	2.42	2.46	2.32	2.29	2.72	3.14	3.50	3.41
Income Tax Expense	5.36	-23	3.43	6.21	5.49	-8.09	7.03	5.05	8.72	9.07	10
Basic Earnings per Share	($0.20)	$0.37	($0.25)	($0.06)	($0.18)	($0.11)	$0.12	$0.24	$0.25	$0.19	$0.30
Weighted Average Basic Shares Outstanding	70.19M	70.06M	70.63M	71.00M	71.73M	71.42M	72.65M	73.44M	74.71M	74.20M	76.52M
Diluted Earnings per Share	($0.20)	$0.37	($0.25)	($0.06)	($0.18)	($0.11)	$0.11	$0.23	$0.23	$0.18	$0.27
Weighted Average Diluted Shares Outstanding	70.19M	71.92M	70.63M	71.00M	71.73M	71.42M	76.15M	77.94M	80.04M	78.98M	82.41M
Weighted Average Basic & Diluted Shares Outstanding	140.68M	141.23M	141.88M	142.49M	144.40M	145.29M	145.94M	148.22M	151.59M	153.07M	153.88M

This table details how cash moves in and out of Kiniksa Pharmaceuticals International's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-10	27	-25	67	8.22	0.25	-15	76	-18
Net Cash From Operating Activities	-50	-81	-158	-137	-126	5.81	13	26	138
Net Cash From Continuing Operating Activities	-50	-81	-158	-137	-126	5.81	13	26	138
Net Income / (Loss) Continuing Operations	-65	-103	-162	-161	-158	183	14	-43	59
Consolidated Net Income / (Loss)	-65	-103	-162	-161	-158	183	14	-43	59
Depreciation Expense	0.03	0.29	2.07	2.41	2.36	2.40	2.34	1.70	1.55
Amortization Expense	0.00	-1.42	-3.50	0.12	0.66	-0.08	-1.07	0.44	-0.92
Non-Cash Adjustments To Reconcile Net Income	0.90	6.00	24	21	25	18	35	30	50
Changes in Operating Assets and Liabilities, net	14	17	-19	1.75	3.24	-197	-37	37	28
Net Cash From Investing Activities	-0.07	-239	49	-23	129	-8.08	-30	38	-189
Net Cash From Continuing Investing Activities	-0.07	-239	49	-23	129	-8.08	-30	38	-189
Purchase of Property, Plant & Equipment	-0.07	-5.29	-3.20	-0.28	-0.42	-0.11	-0.13	-0.43	-1.57
Purchase of Investments	0.00	-402	-489	-430	-157	-136	-205	-202	-387
Sale of Property, Plant & Equipment	-	-	-	0.00	0.00	0.09	0.00	0.03	0.00
Sale and/or Maturity of Investments	0.00	168	541	407	306	128	176	240	199
Net Cash From Financing Activities	40	347	84	227	5.89	2.52	1.50	12	33
Net Cash From Continuing Financing Activities	40	347	84	227	5.89	2.52	1.50	12	33
Issuance of Common Equity	0.00	159	84	228	5.89	3.42	3.70	17	41
Other Financing Activities, net	0.00	0.38	-	0.00	0.00	-0.90	-2.21	-4.98	-7.73
Cash Income Taxes Paid	0.29	0.38	1.72	0.48	1.28	11	5.61	2.00	3.01

This table details how cash moves in and out of Kiniksa Pharmaceuticals International's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	5.26	-9.87	33	-42	-1.90	86	-26	35	-17	-9.26	24
Net Cash From Operating Activities	17	4.33	3.99	5.17	-2.24	19	22	28	34	54	50
Net Cash From Continuing Operating Activities	17	4.33	3.99	5.19	-2.26	19	22	28	34	54	50
Net Income / (Loss) Continuing Operations	-14	25	-18	-3.91	-13	-8.89	8.54	18	18	14	23
Consolidated Net Income / (Loss)	-14	25	-18	-3.91	-13	-8.89	8.54	18	18	14	23
Depreciation Expense	0.60	0.54	0.47	0.43	0.40	0.40	0.35	0.36	0.38	0.47	0.47
Amortization Expense	1.44	-0.30	0.30	-0.19	-0.49	0.82	0.26	-0.84	0.60	-0.93	1.30
Non-Cash Adjustments To Reconcile Net Income	6.75	-34	6.70	22	-7.26	16	7.74	8.84	10	23	10
Changes in Operating Assets and Liabilities, net	22	12	14	-13	18	10	5.44	1.90	3.97	17	16
Net Cash From Investing Activities	-12	-15	26	-47	-6.35	65	-52	-3.88	-63	-71	-32
Net Cash From Continuing Investing Activities	-12	-15	26	-47	-6.35	65	-52	-3.88	-63	-71	-32
Purchase of Property, Plant & Equipment	-0.02	-0.06	-0.08	-	-	-0.19	-0.10	-0.17	-0.67	-0.63	-0.16
Purchase of Investments	-53	-61	-36	-89	-54	-22	-95	-34	-146	-111	-177
Sale and/or Maturity of Investments	41	46	62	42	48	87	44	31	84	41	146
Net Cash From Financing Activities	0.55	0.70	3.61	-0.18	6.69	2.14	2.77	11	12	7.66	6.07
Net Cash From Continuing Financing Activities	0.55	0.70	3.61	-0.18	6.69	2.14	2.77	11	12	7.66	6.07
Issuance of Common Equity	1.66	0.96	3.99	1.14	9.40	2.72	3.18	13	16	8.58	6.39
Other Financing Activities, net	-1.11	-0.26	-0.38	-1.31	-2.71	-0.58	-0.41	-2.05	-4.35	-0.92	-0.32
Cash Income Taxes Paid	0.20	-1.31	0.00	1.51	-0.77	1.26	3.01	0.00	-	0.00	0.00

This table presents Kiniksa Pharmaceuticals International's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	47	322	255	349	233	460	526	581	764
Total Current Assets	47	314	242	333	196	243	276	332	527
Cash & Equivalents	46	72	47	114	122	123	108	184	166
Short-Term Investments	0.00	235	186	209	60	68	98	60	248
Accounts Receivable	-	-	-	0.00	3.99	13	21	42	16
Inventories, net	-	-	-	0.00	3.68	22	31	26	55
Prepaid Expenses	1.44	6.45	8.25	9.56	6.59	11	18	20	43
Plant, Property, & Equipment, net	0.13	6.36	6.40	4.05	2.83	1.66	0.73	0.66	1.94
Total Noncurrent Assets	0.26	1.86	6.51	12	34	215	249	248	235
Intangible Assets	-	-	-	0.00	19	18	17	16	15
Noncurrent Deferred & Refundable Income Taxes	0.24	1.22	4.37	0.01	0.00	185	219	211	198
Other Noncurrent Operating Assets	0.03	0.64	2.14	12	14	11	13	21	21
Total Liabilities & Shareholders' Equity	47	322	255	349	233	460	526	581	764
Total Liabilities	17	43	29	38	48	64	87	142	196
Total Current Liabilities	17	43	28	32	45	47	64	101	139
Accounts Payable	1.22	11	5.69	0.50	1.87	7.90	8.25	2.04	2.03
Accrued Expenses	16	31	20	29	38	30	45	81	112
Other Current Liabilities	0.00	0.22	1.72	2.14	4.93	9.06	10	18	25
Total Noncurrent Liabilities	0.00	0.14	1.28	5.68	2.94	16	24	41	57
Noncurrent Deferred Revenue	-	-	-	-	0.00	12	12	32	32
Other Noncurrent Operating Liabilities	-	0.14	1.28	5.68	2.94	4.46	12	9.69	25
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-90	279	225	312	185	396	439	438	568
Total Preferred & Common Equity	-90	279	225	312	185	396	439	438	568
Total Common Equity	-90	279	225	312	185	396	439	438	568
Common Stock	1.29	473	581	829	861	888	917	960	1,030
Retained Earnings	-91	-194	-356	-517	-675	-492	-478	-521	-462
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.00	0.03	-0.03	-0.07	0.04	0.01	-0.16	-0.03

This table presents Kiniksa Pharmaceuticals International's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	460	443	484	483	520	542	555	599	661	712	825
Total Current Assets	242	232	246	256	271	301	311	356	420	476	594
Cash & Equivalents	176	81	113	118	141	99	97	157	192	175	190
Short-Term Investments	25	107	72	83	72	119	126	111	116	177	278
Accounts Receivable	11	7.42	25	3.04	16	20	25	40	32	52	23
Inventories, net	15	23	24	26	27	35	29	22	48	41	73
Prepaid Expenses	15	13	12	26	14	27	34	25	32	30	30
Plant, Property, & Equipment, net	2.00	1.39	1.14	0.92	0.71	0.63	0.56	0.61	1.08	1.66	1.99
Total Noncurrent Assets	216	210	237	226	248	241	243	243	240	235	229
Intangible Assets	19	18	18	18	17	17	17	16	16	16	15
Noncurrent Deferred & Refundable Income Taxes	186	184	204	194	215	204	208	208	206	201	194
Other Noncurrent Operating Assets	12	7.55	16	15	16	20	19	19	18	18	20
Total Liabilities & Shareholders' Equity	460	443	484	483	520	542	555	599	661	712	825
Total Liabilities	76	53	73	78	88	107	118	142	166	177	220
Total Current Liabilities	56	37	47	53	64	84	96	97	118	124	157
Accounts Payable	1.47	1.39	0.65	1.01	5.63	7.39	8.33	1.98	8.96	6.15	24
Accrued Expenses	31	21	35	41	45	63	70	76	88	94	108
Other Current Liabilities	12	7.82	6.83	8.74	14	14	18	19	21	23	24
Total Noncurrent Liabilities	19	16	25	24	24	23	22	45	48	53	63
Noncurrent Deferred Revenue	14	12	12	12	12	12	12	32	32	32	32
Other Noncurrent Operating Liabilities	5.26	4.02	13	13	12	11	11	13	17	22	31
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	384	390	412	405	432	435	437	457	495	535	606
Total Preferred & Common Equity	384	390	412	405	432	435	437	457	495	535	606
Total Common Equity	384	390	412	405	432	435	437	457	495	535	606
Common Stock	881	894	901	908	928	935	949	970	990	1,012	1,046
Retained Earnings	-496	-504	-489	-503	-496	-500	-512	-513	-495	-476	-440
Accumulated Other Comprehensive Income / (Loss)	-0.07	0.06	0.01	-0.00	-0.05	-0.13	-0.04	-0.17	-0.05	-0.16	-0.67

This table displays calculated financial ratios and metrics derived from Kiniksa Pharmaceuticals International's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	471.24%	22.74%	56.61%	60.09%
EBITDA Growth	0.00%	-67.19%	-56.82%	10.32%	0.12%	108.69%	-215.23%	-121.18%	363.13%
EBIT Growth	0.00%	-65.38%	-57.14%	8.08%	-0.20%	107.04%	-251.02%	-117.10%	345.82%
NOPAT Growth	0.00%	-65.38%	-57.14%	7.41%	0.46%	248.23%	-110.85%	-81.04%	260.57%
Net Income Growth	0.00%	-59.12%	-56.81%	0.30%	2.14%	216.11%	-92.32%	-406.68%	236.61%
EPS Growth	0.00%	90.27%	14.33%	12.71%	11.88%	213.04%	-92.31%	-400.00%	225.00%
Operating Cash Flow Growth	0.00%	-61.32%	-95.49%	13.79%	7.50%	104.60%	129.05%	93.14%	437.14%
Free Cash Flow Firm Growth	0.00%	0.00%	-119.77%	23.52%	-16.82%	67.66%	-10.91%	112.85%	1,515.78%
Invested Capital Growth	0.00%	-79.75%	71.62%	-47.76%	124.12%	7,147.57%	13.10%	-16.20%	-21.19%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	94.68%	24.37%	8.65%	10.19%	13.31%
EBITDA Q/Q Growth	0.00%	0.00%	6.63%	-13.57%	9.78%	144.83%	-41.96%	-118.58%	75.71%
EBIT Q/Q Growth	0.00%	0.00%	6.36%	-14.00%	9.73%	134.03%	-35.81%	-116.18%	82.78%
NOPAT Q/Q Growth	0.00%	0.00%	6.36%	-14.82%	9.67%	816.49%	-31.02%	-73.87%	81.90%
Net Income Q/Q Growth	0.00%	0.00%	6.25%	-15.67%	9.89%	28.61%	310.46%	-376.32%	64.28%
EPS Q/Q Growth	0.00%	0.00%	-239.72%	-11.54%	11.20%	30.00%	300.00%	-400.00%	63.04%
Operating Cash Flow Q/Q Growth	0.00%	-5.55%	2.14%	-14.24%	15.01%	486.88%	611.58%	128.47%	34.15%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-9.78%	11.97%	79.08%	-30.23%	120.79%	59.21%
Invested Capital Q/Q Growth	0.00%	0.00%	-16.43%	-99.75%	-79.55%	12.14%	13.93%	-8.64%	-16.23%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	74.22%	78.67%	66.72%	55.29%	54.66%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	-398.30%	6.06%	-5.69%	-8.04%	13.21%
Operating Margin	0.00%	0.00%	0.00%	0.00%	-406.38%	4.44%	-9.32%	-10.78%	11.40%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	-406.13%	5.01%	-6.16%	-8.54%	13.12%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	-409.72%	83.28%	5.21%	-10.21%	8.71%
Tax Burden Percent	100.00%	99.79%	98.75%	103.30%	100.88%	1,663.01%	-84.58%	119.48%	66.40%
Interest Burden Percent	99.19%	95.64%	96.44%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	-1,563.01%	0.00%	0.00%	33.60%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	155.99%	-8.05%	-14.95%	29.44%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	144.81%	-24.03%	-9.94%	27.09%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	-92.89%	11.43%	5.10%	-17.71%
Return on Equity (ROE)	-215.80%	-66.74%	-64.15%	-60.06%	-63.55%	63.10%	3.37%	-9.85%	11.73%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-4,380.75%	-38.56%	-20.35%	2.68%	53.14%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	-53.77%	3.18%	-3.38%	-6.53%	13.22%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	-54.24%	52.96%	2.86%	-7.80%	8.78%
Return on Common Equity (ROCE)	643.96%	-40.90%	-64.15%	-60.06%	-63.55%	63.10%	3.37%	-9.85%	11.73%
Return on Equity Simple (ROE_SIMPLE)	72.32%	-36.96%	-71.81%	-51.74%	-85.35%	46.29%	3.21%	-9.85%	0.00%
Net Operating Profit after Tax (NOPAT)	-46	-76	-119	-110	-110	163	-18	-32	51
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-284.47%	73.81%	-6.53%	-7.54%	7.57%
Net Nonoperating Expense Percent (NNEP)	-41.82%	-15.59%	-15.87%	-18.39%	-19.09%	11.18%	15.98%	-5.01%	2.35%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	41.03%	-4.02%	-7.28%	9.03%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	25.78%	21.33%	33.28%	44.71%	45.34%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	222.99%	44.49%	47.89%	39.70%	28.97%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	257.62%	29.74%	28.16%	26.37%	14.29%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	480.61%	74.23%	76.05%	66.07%	43.26%
Earnings before Interest and Taxes (EBIT)	-65	-108	-170	-156	-157	11	-17	-36	89
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-65	-109	-171	-154	-154	13	-15	-34	90
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	9.95	5.39	7.71	8.76	5.26	5.62	6.51	11.02
Price to Tangible Book Value (P/TBV)	0.00	9.95	5.39	7.71	9.78	5.51	5.85	6.77	11.32
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	42.07	9.46	9.13	6.75	9.23
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	11.36	175.20	0.00	105.98
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	8.80%	0.57%	0.00%	0.94%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	507.56	9.21	9.73	13.41	38.03
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	37.35	8.60	8.37	6.17	8.62
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	141.81	0.00	0.00	65.24
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	171.65	0.00	0.00	65.71
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	11.64	0.00	0.00	113.88
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	325.91	169.99	101.70	42.32
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	456.14	63.09
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.52	-1.14	-1.07	-1.04	-1.02	-0.64	-0.48	-0.51	-0.65
Leverage Ratio	1.58	1.19	1.14	1.12	1.17	1.19	1.18	1.26	1.34
Compound Leverage Factor	1.57	1.14	1.10	1.12	1.17	1.19	1.18	1.26	1.34
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	398.41%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-298.41%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.22	38.11	21.87	35.95	15.04	19.25	16.55	11.80	20.17
Noncontrolling Interest Sharing Ratio	398.41%	38.72%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	2.70	7.37	8.68	10.46	4.38	5.16	4.34	3.30	3.79
Quick Ratio	2.61	7.22	8.39	10.16	4.15	4.32	3.58	2.84	3.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-63	-139	-106	-124	-40	-45	5.73	93
Operating Cash Flow to CapEx	-72,781.16%	-1,531.42%	-4,944.40%	-48,244.52%	-30,433.25%	41,478.57%	10,231.54%	10,194.05%	8,800.06%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.13	0.64	0.55	0.76	1.01
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	26.46	15.93	13.44	23.64
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	3.72	3.41	6.58	7.56
Fixed Asset Turnover	0.00	0.00	0.00	0.00	11.20	98.03	225.97	606.36	520.20
Accounts Payable Turnover	0.00	0.00	0.00	0.00	8.38	9.62	11.14	36.80	151.08
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	13.80	22.91	27.16	15.44
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	98.21	106.99	55.44	48.27
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	43.55	37.95	32.76	9.92	2.42
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	-43.55	74.05	97.13	72.69	61.29
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	-16	-28	-7.96	-12	2.84	206	232	195	154
Invested Capital Turnover	0.00	0.00	0.00	0.00	-8.64	2.11	1.23	1.98	3.89
Increase / (Decrease) in Invested Capital	0.00	-12	20	-3.80	15	203	27	-38	-41
Enterprise Value (EV)	227	2,472	981	2,082	1,439	1,893	2,261	2,613	5,839
Market Capitalization	153	2,779	1,214	2,406	1,622	2,083	2,467	2,856	6,253
Book Value per Share	($49.57)	$2.82	$2.05	$2.29	$1.34	$2.85	$3.12	$3.04	$3.74
Tangible Book Value per Share	($49.57)	$2.82	$2.05	$2.29	$1.20	$2.72	$3.00	$2.92	$3.64
Total Capital	30	279	225	312	185	396	439	438	568
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-46	-307	-233	-324	-182	-191	-206	-244	-414
Capital Expenditures (CapEx)	0.07	5.29	3.20	0.28	0.42	0.01	0.13	0.25	1.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-16	-36	-20	-22	-31	5.39	6.26	-12	-26
Debt-free Net Working Capital (DFNWC)	30	271	214	301	152	196	213	231	388
Net Working Capital (NWC)	30	271	214	301	152	196	213	231	388
Net Nonoperating Expense (NNE)	19	28	43	51	48	-21	-32	11	-7.73
Net Nonoperating Obligations (NNO)	-46	-307	-233	-324	-182	-191	-206	-244	-414
Total Depreciation and Amortization (D&A)	0.03	-1.14	-1.43	2.53	3.02	2.32	1.27	2.14	0.64
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	-79.34%	2.45%	2.32%	-2.94%	-3.85%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	393.37%	89.02%	78.68%	54.62%	57.26%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	393.37%	89.02%	78.68%	54.62%	57.26%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($35.85)	($3.49)	($2.99)	($2.61)	($2.30)	$2.64	$0.20	($0.60)	$0.80
Adjusted Weighted Average Basic Shares Outstanding	1.81M	108.66M	111.09M	136.46M	68.58M	69.38M	70.06M	71.42M	74.20M
Adjusted Diluted Earnings per Share	($35.85)	($3.49)	($2.99)	($2.61)	($2.30)	$2.60	$0.20	($0.60)	$0.75
Adjusted Weighted Average Diluted Shares Outstanding	1.81M	108.66M	111.09M	136.46M	68.58M	70.42M	71.92M	71.42M	78.98M
Adjusted Basic & Diluted Earnings per Share	($35.85)	($3.49)	($2.99)	($2.61)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.81M	29.55M	54.05M	61.84M	138.21M	139.51M	141.23M	145.29M	153.07M
Normalized Net Operating Profit after Tax (NOPAT)	-46	-76	-119	-110	-110	6.84	-18	-32	51
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-284.47%	3.11%	-6.53%	-7.54%	7.57%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	-406.13%	5.01%	-6.16%	-8.54%	13.12%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-3.54%	-0.07%	-0.70%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Kiniksa Pharmaceuticals International's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	153,070,754.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	153,070,754.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.15
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-32.37%	34.76%	65.18%	51.99%	67.37%	46.93%	72.54%	44.34%	61.17%	64.95%	55.51%
EBITDA Growth	-113.70%	-62.79%	-37.48%	242.31%	-12.92%	-685.00%	219.63%	779.46%	486.12%	244.71%	113.12%
EBIT Growth	-118.19%	-64.19%	-52.46%	285.96%	15.27%	-793.02%	209.03%	892.93%	477.13%	237.05%	109.96%
NOPAT Growth	-103.44%	-78.84%	-47.75%	108.99%	11.61%	-1,719.11%	162.88%	7,818.33%	341.19%	189.29%	177.87%
Net Income Growth	-106.18%	465.73%	-44.29%	-126.10%	8.39%	-135.22%	148.23%	556.29%	245.24%	259.75%	164.57%
EPS Growth	-106.29%	428.57%	-38.89%	-128.57%	10.00%	-129.73%	144.00%	483.33%	227.78%	263.64%	145.45%
Operating Cash Flow Growth	-72.63%	137.36%	193.44%	238.07%	-113.16%	333.99%	459.92%	443.54%	1,606.13%	187.13%	124.87%
Free Cash Flow Firm Growth	-153.47%	86.87%	85.60%	104.93%	43.88%	192.55%	233.50%	325.88%	390.09%	120.87%	96.81%
Invested Capital Growth	11.33%	13.10%	7.77%	-4.56%	4.50%	-16.20%	-13.37%	-13.46%	-14.04%	-21.19%	-27.26%
Revenue Q/Q Growth	-6.19%	24.38%	-4.24%	36.03%	3.30%	9.20%	12.44%	13.80%	15.34%	11.76%	6.01%
EBITDA Q/Q Growth	-260.82%	141.74%	-601.60%	118.84%	-386.29%	-116.22%	202.57%	38.52%	25.69%	-18.97%	51.06%
EBIT Q/Q Growth	-585.96%	128.83%	-682.69%	116.14%	-412.54%	-135.79%	191.67%	46.98%	18.71%	-14.32%	40.45%
NOPAT Q/Q Growth	-246.45%	110.91%	-1,487.81%	101.71%	-3,506.65%	-99.82%	153.90%	115.82%	3.77%	-26.02%	67.72%
Net Income Q/Q Growth	-192.54%	282.15%	-170.15%	77.93%	-224.80%	29.98%	196.07%	108.83%	3.38%	-22.98%	59.11%
EPS Q/Q Growth	-195.24%	285.00%	-167.57%	76.00%	-200.00%	38.89%	200.00%	109.09%	0.00%	-21.74%	50.00%
Operating Cash Flow Q/Q Growth	553.81%	-74.54%	-7.82%	29.62%	-143.27%	939.45%	18.93%	25.83%	19.89%	60.03%	-6.86%
Free Cash Flow Firm Q/Q Growth	86.70%	8.15%	-4.71%	138.52%	-251.48%	251.47%	51.04%	22.90%	3.18%	15.33%	34.58%
Invested Capital Q/Q Growth	-9.98%	13.93%	-6.08%	-0.92%	-1.44%	-8.64%	-2.91%	-1.02%	-2.11%	-16.23%	-10.38%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	60.63%	68.20%	60.70%	61.03%	55.96%	46.07%	55.25%	54.71%	53.80%	54.99%	55.02%
EBITDA Margin	-9.63%	3.23%	-16.92%	2.34%	-6.50%	-12.86%	11.73%	14.28%	15.56%	11.28%	16.08%
Operating Margin	-16.30%	0.10%	-20.71%	-0.11%	-8.61%	-15.75%	9.63%	12.86%	13.28%	9.78%	13.66%
EBIT Margin	-12.68%	2.94%	-17.88%	2.12%	-6.42%	-13.86%	11.30%	14.59%	15.02%	11.51%	15.25%
Profit (Net Income) Margin	-20.66%	30.26%	-22.17%	-3.60%	-11.31%	-7.25%	6.20%	11.37%	10.19%	7.02%	10.54%
Tax Burden Percent	163.02%	1,030.08%	124.01%	-169.62%	176.27%	52.35%	54.86%	77.95%	67.88%	61.02%	69.13%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	-930.08%	0.00%	269.62%	0.00%	0.00%	45.14%	22.05%	32.12%	38.98%	30.87%
Return on Invested Capital (ROIC)	-14.65%	1.23%	-20.79%	0.28%	-11.09%	-21.84%	12.48%	26.29%	27.19%	23.22%	43.58%
ROIC Less NNEP Spread (ROIC-NNEP)	-11.56%	-11.06%	-17.74%	2.31%	-8.30%	-23.90%	11.96%	25.49%	26.46%	22.57%	42.94%
Return on Net Nonoperating Assets (RNNOA)	5.89%	5.26%	8.65%	-1.10%	4.19%	12.26%	-6.48%	-14.43%	-15.67%	-14.75%	-29.74%
Return on Equity (ROE)	-8.77%	6.49%	-12.14%	-0.82%	-6.90%	-9.58%	6.00%	11.86%	11.53%	8.46%	13.84%
Cash Return on Invested Capital (CROIC)	-17.67%	-20.35%	-17.64%	-4.03%	-13.20%	2.68%	8.90%	15.17%	29.32%	53.14%	70.89%
Operating Return on Assets (OROA)	-6.69%	1.61%	-11.21%	1.40%	-4.75%	-10.60%	9.72%	12.83%	14.17%	11.61%	16.15%
Return on Assets (ROA)	-10.90%	16.59%	-13.90%	-2.38%	-8.37%	-5.55%	5.33%	10.00%	9.62%	7.08%	11.16%
Return on Common Equity (ROCE)	-8.77%	6.49%	-12.14%	-0.82%	-6.90%	-9.58%	6.00%	11.86%	11.53%	8.46%	13.84%
Return on Equity Simple (ROE_SIMPLE)	-1.65%	0.00%	2.00%	-2.35%	-2.08%	0.00%	-3.71%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-7.65	0.83	-12	0.20	-6.76	-14	7.28	16	16	12	20
NOPAT Margin	-11.41%	1.00%	-14.50%	0.18%	-6.02%	-11.02%	5.28%	10.02%	9.02%	5.97%	9.44%
Net Nonoperating Expense Percent (NNEP)	-3.09%	12.29%	-3.05%	-2.03%	-2.79%	2.05%	0.52%	0.80%	0.74%	0.65%	0.64%
Return On Investment Capital (ROIC_SIMPLE)	-	0.19%	-	-	-	-3.08%	1.59%	3.17%	3.05%	2.13%	3.34%
Cost of Revenue to Revenue	39.37%	31.80%	39.30%	38.97%	44.04%	53.93%	44.75%	45.29%	46.21%	45.01%	44.98%
SG&A Expenses to Revenue	51.41%	44.05%	48.44%	39.03%	41.35%	33.08%	31.59%	29.89%	27.15%	28.09%	28.54%
R&D to Revenue	25.51%	24.04%	32.98%	22.11%	23.22%	28.74%	14.03%	11.96%	13.36%	17.12%	12.82%
Operating Expenses to Revenue	76.92%	68.10%	81.41%	61.14%	64.57%	61.82%	45.62%	41.85%	40.51%	45.21%	41.36%
Earnings before Interest and Taxes (EBIT)	-8.50	2.45	-14	2.30	-7.20	-17	16	23	27	23	33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.46	2.69	-14	2.55	-7.29	-16	16	22	28	23	34
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.02	5.62	6.43	6.09	8.15	6.51	7.05	8.16	10.75	11.02	12.17
Price to Tangible Book Value (P/TBV)	6.29	5.85	6.69	6.33	8.47	6.77	7.31	8.43	11.07	11.32	12.48
Price to Revenue (P/Rev)	9.80	9.13	9.20	7.82	9.27	6.75	6.71	7.63	9.62	9.23	9.77
Price to Earnings (P/E)	0.00	175.20	320.87	0.00	0.00	0.00	0.00	829.71	159.89	105.98	100.88
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.57%	0.31%	0.00%	0.00%	0.00%	0.00%	0.12%	0.63%	0.94%	0.99%
Enterprise Value to Invested Capital (EV/IC)	10.96	9.73	11.73	11.23	15.65	13.41	15.64	19.92	29.48	38.03	50.16
Enterprise Value to Revenue (EV/Rev)	8.99	8.37	8.49	7.17	8.69	6.17	6.15	7.05	9.04	8.62	9.15
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	240.56	106.07	65.24	64.03
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	261.56	111.13	65.71	65.13
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2,482.05	191.69	113.88	107.42
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	169.99	118.86	79.77	296.78	101.70	67.20	55.72	52.53	42.32	41.62
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	456.14	163.16	121.85	92.95	63.09	59.60
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.51	-0.48	-0.49	-0.48	-0.50	-0.51	-0.54	-0.57	-0.59	-0.65	-0.69
Leverage Ratio	1.20	1.18	1.17	1.21	1.23	1.26	1.26	1.29	1.30	1.34	1.34
Compound Leverage Factor	1.20	1.18	1.17	1.21	1.23	1.26	1.26	1.29	1.30	1.34	1.34
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	18.27	16.67	18.60	14.64	17.88	11.91	13.86	15.00	20.14	19.89	21.07
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.79	4.34	4.21	3.57	3.24	3.30	3.66	3.57	3.85	3.79	3.79
Quick Ratio	3.82	3.58	3.57	2.84	2.59	2.84	3.17	2.88	3.27	3.09	3.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-28	-26	-27	11	-16	24	36	45	46	53	72
Operating Cash Flow to CapEx	106,162.50%	7,723.21%	4,746.43%	0.00%	0.00%	9,725.39%	22,549.49%	17,024.24%	5,018.93%	8,514.06%	31,179.50%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.53	0.55	0.63	0.66	0.74	0.76	0.86	0.88	0.94	1.01	1.06
Accounts Receivable Turnover	35.03	15.93	25.77	15.03	27.51	13.44	17.17	20.22	15.61	23.64	23.83
Inventory Turnover	3.86	3.41	4.18	4.31	5.52	6.58	8.90	5.98	8.06	7.56	7.18
Fixed Asset Turnover	170.78	225.97	286.72	384.93	519.40	606.36	730.15	622.38	539.69	520.20	581.82
Accounts Payable Turnover	62.59	11.14	30.18	31.50	32.05	36.80	57.66	30.36	39.00	151.08	25.92
Days Sales Outstanding (DSO)	10.42	22.91	14.16	24.29	13.27	27.16	21.26	18.05	23.39	15.44	15.32
Days Inventory Outstanding (DIO)	94.50	106.99	87.30	84.76	66.17	55.44	41.03	61.06	45.30	48.27	50.82
Days Payable Outstanding (DPO)	5.83	32.76	12.09	11.59	11.39	9.92	6.33	12.02	9.36	2.42	14.08
Cash Conversion Cycle (CCC)	99.09	97.13	89.37	97.46	68.05	72.69	55.96	67.09	59.33	61.29	52.05
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	204	232	218	216	213	195	189	187	183	154	138
Invested Capital Turnover	1.28	1.23	1.43	1.53	1.84	1.98	2.36	2.62	3.02	3.89	4.62
Increase / (Decrease) in Invested Capital	21	27	16	-10	9.18	-38	-29	-29	-30	-41	-52
Enterprise Value (EV)	2,237	2,261	2,562	2,430	3,337	2,613	2,959	3,730	5,403	5,839	6,902
Market Capitalization	2,438	2,467	2,776	2,649	3,561	2,856	3,227	4,038	5,755	6,253	7,370
Book Value per Share	$2.89	$3.12	$6.11	$3.07	$3.07	$3.04	$3.15	$3.39	$3.61	$3.74	$3.96
Tangible Book Value per Share	$2.76	$3.00	$5.87	$2.95	$2.95	$2.92	$3.04	$3.28	$3.51	$3.64	$3.86
Total Capital	405	439	432	435	437	438	457	495	535	568	606
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-201	-206	-214	-219	-224	-244	-268	-308	-352	-414	-468
Capital Expenditures (CapEx)	0.02	0.06	0.08	0.00	0.00	0.19	0.10	0.17	0.67	0.63	0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.56	6.26	-7.17	-2.03	-8.43	-12	-9.70	-5.30	-0.16	-26	-31
Debt-free Net Working Capital (DFNWC)	203	213	206	217	215	231	259	302	352	388	438
Net Working Capital (NWC)	203	213	206	217	215	231	259	302	352	388	438
Net Nonoperating Expense (NNE)	6.21	-24	6.12	4.11	5.93	-4.62	-1.26	-2.12	-2.13	-2.14	-2.36
Net Nonoperating Obligations (NNO)	-201	-206	-214	-219	-224	-244	-268	-308	-352	-414	-468
Total Depreciation and Amortization (D&A)	2.04	0.24	0.76	0.24	-0.09	1.22	0.60	-0.49	0.99	-0.46	1.77
Debt-free, Cash-free Net Working Capital to Revenue	0.63%	2.32%	-2.38%	-0.60%	-2.20%	-2.94%	-2.02%	-1.00%	-0.03%	-3.85%	-4.05%
Debt-free Net Working Capital to Revenue	81.46%	78.68%	68.39%	63.95%	56.07%	54.62%	53.75%	57.14%	58.86%	57.26%	58.03%
Net Working Capital to Revenue	81.46%	78.68%	68.39%	63.95%	56.07%	54.62%	53.75%	57.14%	58.86%	57.26%	58.03%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.20)	$0.37	($0.25)	($0.06)	($0.18)	($0.11)	$0.12	$0.24	$0.25	$0.19	$0.30
Adjusted Weighted Average Basic Shares Outstanding	70.19M	70.06M	70.63M	71.00M	71.73M	71.42M	72.65M	73.44M	74.71M	74.20M	76.52M
Adjusted Diluted Earnings per Share	($0.20)	$0.37	($0.25)	($0.06)	($0.18)	($0.11)	$0.11	$0.23	$0.23	$0.18	$0.27
Adjusted Weighted Average Diluted Shares Outstanding	70.19M	71.92M	70.63M	71.00M	71.73M	71.42M	76.15M	77.94M	80.04M	78.98M	82.41M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	140.68M	141.23M	141.88M	142.49M	144.40M	145.29M	145.94M	148.22M	151.59M	153.07M	153.88M
Normalized Net Operating Profit after Tax (NOPAT)	-7.65	0.06	-12	-0.08	-6.76	-14	7.28	16	16	12	20
Normalized NOPAT Margin	-11.41%	0.07%	-14.50%	-0.08%	-6.02%	-11.02%	5.28%	10.02%	9.02%	5.97%	9.44%
Pre Tax Income Margin	-12.68%	2.94%	-17.88%	2.12%	-6.42%	-13.86%	11.30%	14.59%	15.02%	11.51%	15.25%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) has shown a clear shift in momentum in 2025 based on the latest four quarters of results. Top-line growth, improving profitability, and solid operating cash flow are the headline trends, but investors should note heavy investing activity that has affected cash balances.

Revenue growth in 2025: Q4 2025 revenue reached $202.1M, up from $122.5M in Q4 2024 (roughly +65%), indicating stronger year-over-year demand.
Consistent quarterly profitability in 2025: All four 2025 quarters reported positive net income attributable to common shareholders (Q1 about $8.5M, Q2 ~$17.8M, Q3 ~$18.4M, Q4 ~$14.2M).
Robust operating cash flow in 2025: Operating cash flow remained solid, with Q4 2025 net cash from continuing operating activities around $53.9M and positive cash flow in each 2025 quarter (Q3 ~$33.7M, Q2 ~$28.1M, Q1 ~$22.3M).
Healthy gross margins: Gross margin stayed in the mid-50% range across 2025 (roughly 54–55%), signaling efficient cost of goods and pricing.
Strong liquidity position by late 2025: Cash & equivalents around $174.9M (Q3 2025) and total assets near $712M, with total equity around $535M, providing a solid liquidity and balance-sheet cushion.

Significant investing activity in 2025: Substantial net cash used for investing (approx. $343M across four quarters: Q1 -$51.5M, Q2 -$34.3M, Q3 -$146.2M, Q4 -$111.0M) driven largely by purchases of investments and other investing outflows. This reduces near-term liquidity even with strong operating cash flow.
Historical restatements noted: Prior quarters show restatements (e.g., Q3 2024 restated, Q2 2024 restated, Q1 2024 restated), which can complicate comparability and investor due diligence.

Large year-to-date investing pressure on cash: The heavy investing outflows in 2025 (≈$343M) could pose liquidity risk if operating performance softens or if financing conditions tighten.
Equity dilution in 2025: Issuance of common equity over 2025 (roughly $40.8M in aggregate across Q1–Q4) diluted existing shareholders to some degree.
Prior-year profitability volatility: Notable softness in late 2024 (e.g., Q4 2024 net income to common was negative), highlighting ongoing earnings volatility prior to the 2025 rebound.

05/09/26 11:08 AM ETAI Generated. May Contain Errors.

Kiniksa Pharmaceuticals International Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Kiniksa Pharmaceuticals International's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Kiniksa Pharmaceuticals International's net income appears to be on a downward trend, with a most recent value of $59.01 million in 2025, falling from -$64.87 million in 2017. The previous period was -$43.19 million in 2024. See where experts think Kiniksa Pharmaceuticals International is headed by visiting Kiniksa Pharmaceuticals International's forecast page.

Kiniksa Pharmaceuticals International's total operating income in 2025 was $77.22 million, based on the following breakdown:

Total Gross Profit: $370.35 million
Total Operating Expenses: $293.13 million

Over the last 8 years, Kiniksa Pharmaceuticals International's total revenue changed from $0.00 in 2017 to $677.56 million in 2025, a change of 67,756,400,000.0%.

Kiniksa Pharmaceuticals International's total liabilities were at $196.03 million at the end of 2025, a 37.9% increase from 2024, and a 1,024.7% increase since 2017.

In the past 8 years, Kiniksa Pharmaceuticals International's cash and equivalents has ranged from $45.56 million in 2017 to $183.58 million in 2024, and is currently $165.60 million as of their latest financial filing in 2025.

Over the last 8 years, Kiniksa Pharmaceuticals International's book value per share changed from -49.57 in 2017 to 3.74 in 2025, a change of -107.6%.

Related Companies

Financial statements for NASDAQ:KNSA last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiniksa Pharmaceuticals International (KNSA) Financials

Financials Breakdown Chart

Key Financial Trends

Kiniksa Pharmaceuticals International Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiniksa Pharmaceuticals International (KNSA) Financials

Annual Income Statements for Kiniksa Pharmaceuticals International

Quarterly Income Statements for Kiniksa Pharmaceuticals International

Annual Cash Flow Statements for Kiniksa Pharmaceuticals International

Quarterly Cash Flow Statements for Kiniksa Pharmaceuticals International

Annual Balance Sheets for Kiniksa Pharmaceuticals International

Quarterly Balance Sheets for Kiniksa Pharmaceuticals International

Annual Metrics And Ratios for Kiniksa Pharmaceuticals International

Quarterly Metrics And Ratios for Kiniksa Pharmaceuticals International

Financials Breakdown Chart

Key Financial Trends

Kiniksa Pharmaceuticals International Financials - Frequently Asked Questions

When does Kiniksa Pharmaceuticals International's financial year end?

How has Kiniksa Pharmaceuticals International's net income changed over the last 8 years?

What is Kiniksa Pharmaceuticals International's operating income?

How has Kiniksa Pharmaceuticals International's revenue changed over the last 8 years?

How much debt does Kiniksa Pharmaceuticals International have?

How much cash does Kiniksa Pharmaceuticals International have?

How has Kiniksa Pharmaceuticals International's book value per share changed over the last 8 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools